Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL28275596 | 1.00 | CA2 (0.40) | — | |
| Phosphoric Acid SCHEMBL1133295 | 1.00 | CA2 (0.40) | — | |
| Phosphoric Acid SCHEMBL8505699 | 0.96 | CA2 (0.43) | — | |
| Phosphoric Acid SCHEMBL7601322 | 0.96 | CA2 (0.43) | — | |
| Phosphoric Acid SCHEMBL854955 | 0.96 | — | — | |
| Phosphoric Acid SCHEMBL6036466 | 0.96 | CA2 (0.43) | — | |
| Phosphoric Acid SCHEMBL6383668 | 0.96 | CA2 (0.43) | — | |
| Phosphoric Acid SCHEMBL17555384 | 0.96 | CA2 (0.43) | — | |
| Phosphoric Acid SCHEMBL675651 | 0.96 | — | — | |
| Phosphoric Acid SCHEMBL4453244 | 0.96 | CA2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115166094-A | Method for detecting toltrazuril content | 镇江威特药业有限责任公司 | 2022-10-11 | — | — | CN | claimed |
| CN-106053676-A | High performance liquid chromatography detection method for tryptophan in fodder | 四川威尔检测技术股份有限公司 | 2016-10-26 | — | — | CN | claimed |
| CN-120154571-A | Cabergol Lin Changxiao injection and preparation method and application thereof | 西北农林科技大学 | 2025-06-17 | — | — | CN | disclosed |
| CN-115850169-B | Preparation method of cis-atracurium besylate impurity and intermediate thereof | 上海医药集团(本溪)北方药业有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-118150745-B | Method for simultaneously determining multiple genotoxic impurities in raw material medicine of lebsiella | 中节能万润股份有限公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-118150745-A | Method for simultaneously determining multiple genotoxic impurities in raw material medicine of lebsiella | 中节能万润股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-115166094-A | Method for detecting toltrazuril content | 镇江威特药业有限责任公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-115166094-A | Method for detecting toltrazuril content | 镇江威特药业有限责任公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-114685317-A | Preparation method of medicine for treating epilepsy | 成都硕德药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-110582203-B | Antimicrobial nonwoven wet wipe in combination with nonionic binders | 瓦克化学股份公司 | 2022-06-21 | — | — | CN | disclosed |
| US-11326132-B2 | Antimicrobial nonwoven wet wipe bonded with a nonionic binder | WACKER CHEMIE AG (DE) | 2022-05-10 | — | — | US | disclosed |
| CN-1969983-A | Quality control method of cough-stopping (Ke Ke) capsule | GUIZHOU YIBAI PHARMACEUTICAL (CN) | 2007-05-30 | — | — | CN | disclosed |
| EP-1550725-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE alpha-METHYLCYSTEINE DERIVATIVE | KANEKA CORPORATION (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-1534340-A2 | CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO | Insert Therapeutics Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040077595-A1 | Having covalently coupled bioactive agent and targeting ligand; controlled release; stability, solubility; reduced toxicity | INSERT THERAPEUTICS, INC. (US) | 2004-04-22 | — | — | US | disclosed |
| WO-2004022099-A2 | CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO | INSERT THERAPEUTICS, INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2000024775-A9 | GENE CLUSTER INVOLVED IN NOGALAMYCIN BIOSYNTHESIS, AND ITS USE IN PRODUCTION OF HYBRID ANTIBIOTICS | GALILAEUS OY (FI) | 2000-08-24 | — | — | WO | disclosed |
| CN-1111910-A | Mammamodulin, a hormone-independent mammary tumor cells specific protein | HOFFMANN LA ROCHE (CH) | 1995-11-15 | — | — | CN | disclosed |
| WO-1994016319-A1 | ANALYSIS METHOD | NILSSON KURT (SE) | 1994-07-21 | — | — | WO | disclosed |
| US-5098576-A | Nonporous silicon carbide as adsorbants for liquid chromatography | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1992-03-24 | — | — | US | disclosed |